Medicinal properties of Peganum harmala L. in traditional Iranian medicine and modern phytotherapy: a review Mina Cheraghi Niroumand, Mohammad Hosein Farzaei, Gholamreza Amin Journal of Traditional Chinese Medicine, 2015, 35, (1), 104-109. Abstract OBJECTIVE : To review the pharmacological activities of Peganum harmala L. (P. harmala, Nitrariaceae) in traditional Iranian medicine (TIM) and modern phytotherapy. METHODS : Opinions of TIM and modern phytotherapy about safety and acceptable dosage of this plant are discussed. Various medical properties of P. harmala were collected from important TIM references and added to scientific reports derived from modern medical databases like PubMed, Scirus, ScienceDirect and Scopus. RESULTS : The main medicinal [...]
Lire la suiteEmerging from the dark side : new therapeutic applications of scheduled psychoactive substances Edward James, Thomas L. Robertshaw & Andrew D. Westwell Future medicinal chemistry, February 2019 Doi : 10.4155/fmc-2018-0447 Keywords : harm reduction • healthcare • MDMA • positive psychology • psilocybin • psychoactive • psychotherapy The discovery and development of new medicines occupies years of painstaking and expensive scientific work, with multidisciplinary teams working together in the hope of developing a new chemical entity that outperforms the current standard of care within the chosen disease setting. Once optimized in the laboratory and achieving acceptable regulatory preclinical benchmarks, years of clinical evaluation are required [...]
Lire la suiteAlkaloids Derived from Tryptophan : Harmine and Related Alkaloids T. D. Nikam, K. M. Nitnaware, and M. L. Ahire chapter 19, in K.G. Ramawat, J.M. Merillon (eds.), Natural Products, # Springer-Verlag, Berlin Heidelberg, 2013 Doi : 10.1007/978-3-642-22144-6_20 Contents 1 Synonyms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 554 2 [...]
Lire la suiteThe Prosocial Effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled Studies in Humans and Laboratory Animals Philip Kamilar-Britt and Gillinder Bedi Neuroscience & Biobehavioral Reviews, 2015, 57, 433–446. doi:10.1016/j.neubiorev.2015.08.016 Abstract Users of ±3,4-Methylenedioxymethamphetamine (MDMA; ‘ecstasy’) report prosocial effects such as sociability and empathy. Supporting these apparently unique social effects, data from controlled laboratory studies indicate that MDMA alters social feelings, information processing, and behavior in humans, and social behavior in rodents. Here, we review this growing body of evidence. In rodents, MDMA increases passive prosocial behavior (adjacent lying) and social reward while decreasing aggression, effects that may involve serotonin 1A receptor mediated oxytocin release interacting with vasopressin receptor [...]
Lire la suiteWhy Psychiatry Needs 3,4 Methylenedioxymeth-amphetamine : A Child Psychiatrist’s Perspective Ben SESSA Neurotherapeutics, 2017, 14, (3), 741-749. doi:10.1007/s13311-017-0531-1 Abstract Since the late 1980s the psychoactive drug 3,4-methylenedioxymethamphetamine (MDMA) has had a well-known history as the recreationally used drug ecstasy. What is less well known by the public is that MDMA started its life as a therapeutic agent and that in recent years an increasing amount of clinical research has been undertaken to revisit the drug’s medical potential. MDMA has unique pharmacological properties that translate well to its proposed agent to assist trauma-focused psychotherapy. Psychological trauma—especially that which arises early in life from child abuse—underpins many [...]
Lire la suiteThe expansion of the field of research on ayahuasca: Some reflections about the ayahuasca track at the 2010 MAPS “Psychedelic Science in the 21st Century” conference Beatriz Caiuby Labate, Clancy Cavnar International Journal of Drug Policy, 2011, 22, 174–178 doi:10.1016/j.drugpo.2010.09.002 A recent conference sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) in collaboration with the Heffter Research Institute, the Beckley Foundation and the Council on Spiritual Practices held from April 15th to 18th 2010, in San José, USA (MAPS, 2010) united 90 presenters and 1100 participants with the goal of giving visibility to studies on the therapeutic potentials of psychedelics (psilocybin,MDMA,ibogaine, ayahuasca, etc.) [...]
Lire la suiteUne université de Houston teste la psilocybine pour la dépression résistante aux traitements - www.NEWSWEED.fr 22 octobre 2019 Aurélien BERNARD Dans la foulée de sa décriminalisation dans quelques villes des États-Unis (Oakland et Denver notamment), la psilocybine intéresse actuellement la communauté scientifique à la recherche de preuves d’efficacité thérapeutique. Des chercheurs du Science Health Center de l’Université du Texas à Houston (UTHealth) ont annoncé qu’ils étudiaient la psilocybine pour la dépression réfractaire aux traitements. PUBLICITE L’étude est inspirée par des recherches scientifiques antérieures qui suggèrent que la psilocybine agit pour créer de nouveaux circuits mentaux. Une étude de 2012 a conclu que la substance pouvait permettre [...]
Lire la suiteHallucinogens and Their Therapeutic Use : A Literature Review Matthew J. BEGOLA, Jason E. SCHILLERSTROM Journal of Psychiatric Practice, 2019, 25, (5), 334–346 Doi : 10.1097/PRA.0000000000000409 The exploration of possible therapeutic benefitsof hallucinogenic substances has undergone a revitalization in the past decade. This literature review investigated the published literature regarding the psychotherapeutic uses of hallucinogens in psychiatric disorders. The results showed that a variety of substances have been evaluated in the treatment of psychiatric disorders, including ayahuasca, ibogaine, ketamine, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin. The conditions treated ranged from depression to autism, with the largest volume of research dedicated to substance use disorders. [...]
Lire la suiteThe Therapeutic Use of Ayahuasca Beatriz Caiuby LABATE, Clancy CAVNAR Editors, Springer-Verlag, Berlin, Heidelberg, 2014 Foreword Ancient Medicine and the Modern World Ayahuasca, the ‘‘great medicine’’ of the Amazon rain forest, was, for millennia, entirely unknown to Western Euro-American civilization. While first scientifically identified, catalogued, and recorded in the mid-nineteenth century by the English botanist and explorer Richard Spruce, it had earlier been the object of brutal suppression by Spanish and Portuguese invaders of the New World who attempted to violently extinguish its ceremonial use by the indigenous people of the Amazon. Employing the harshest measures of the Inquisition, in 1616, the Catholic Church [...]
Lire la suiteAssessment of the Psychotherapeutic Effects of Ritual Ayahuasca Use on Drug Dependency : A Pilot Study Xavier Fernández, Rafael Guimarães dos Santos, Marta Cutchet, Sabela Fondevila, Débora González, Miguel Ángel Alcázar, Jordi Riba, José Carlos Bouso, Josep María Fábregas, Xavier Fernández, Rafael Guimarães dos Santos in "The Therapeutic Use of Ayahuasca", Chapter 11, 183-196 Beatriz Caiuby LABATE, Clancy CAVNAR Editors, Springer-Verlag, Berlin, Heidelberg, 2014 First Online: 23 November 2013 Abstract Using personality, psychopathology, and neuropsychological assessment instruments, our team assessed the therapeutic effects of an ayahuasca ritual treatment. Data was collected at the Institute of Applied Amazonian Ethnopsychology (IDEAA), in the Brazilian Amazon Basin. Psychological assessments [...]
Lire la suite